SCHEMBL20173810

SCHEMBL20173810

CC(C)N1CCCc2cc(C(=O)O)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
MCL1 Q07820 3/20 0.48
RARA P10276 2/20 0.46
RARB P10826 2/20 0.46
RARG P13631 2/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 5/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 3/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20173808 0.92 RARA (0.47) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7670996 0.90 HDAC1 (0.49) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL20178668 0.88 ALDH1A1 (0.51) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7675774 0.85 HDAC1 (0.44) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7675776 0.85 HDAC1 (0.44) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7675768 0.85 HDAC1 (0.44) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7665263 0.84 HDAC1 (0.43) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7665255 0.84 HDAC1 (0.43) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL7669401 0.84 HDAC1 (0.43) ALDH1A1HDAC1HDAC6PDK1PDK2
SCHEMBL20173809 0.83 SRD5A1 (0.54) ALDH1A1HDAC1HDAC6RARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HDAC1 2002/4885HDAC6 597/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HDAC1 2002/4885HDAC6 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.